Research
Everything we build is grounded in rigorous empirical research. We run randomized controlled trials, preregister our analyses, and share our methods and results openly.
Preregistered RCT: MMR Vaccination Intent
We recruited 180 vaccine-hesitant U.S. parents of young children and randomized them to either review MMR content plus have a tailored conversation, or review parallel content on an unrelated topic (car seat safety).
Key Finding
Treatment group parents increased MMR vaccination intent by more than a full point on a 7-point scale (β̂ ≈ 1.03, 95% CI 0.72–1.34). Nearly two-thirds (~64%) increased intent by at least one point, versus only ~10% in the control group.
Effect durability: A follow-up sample (N=66) showed similar effect size after a median of ~2 days (β̂ ≈ 1.09, 95% CI 0.52–1.66).
Mechanism: Transcripts reveal that correcting single misconceptions (e.g., "MMR has no aluminum"), providing actionable plans (what to watch for post-vaccination), and offering ingredient transparency often resolved hesitation.
Sample Participant Responses
"I am more likely to allow my child to receive vaccination knowing it doesn't contain aluminum." Parent who shifted from 1 → 7 on the intent scale after learning MMR contains no aluminum
"I think I have changed my mind since I know they don't include new technology like mRNA." Parent concerned about DNA alteration; shifted 5 points after clarification
"I think a preparation plan makes me more eased up." Parent anxious about side effects; reassured by concrete guidance
"I believe I will go ahead and get it." Parent concerned about ingredient transparency and FDA trust; moved 3 points
"I am okay with the vaccine now. Thank you." Parent after discussing measles risk and school requirements
What's Next
We're building tools ready for clinical deployment and extending this approach to other high-value interventions: colonoscopy, hypertension management, statin initiation, and more. Every new indication will be rigorously evaluated and transparently reported.